Measurement of immune response to vaccination against COVID19 of immunocompromised leukemic patients
Phase 1
Active, not recruiting
- Conditions
- Recipients of cell therapy (allo HSCT, CAR19 T cells) indicated to vaccination against COVID19Therapeutic area: Diseases [C] - Blood and lymphatic diseases [C15]
- Registration Number
- EUCTR2022-000302-10-CZ
- Lead Sponsor
- Institute of hematology and blood transfusion
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Adult recipients of cell therapy (allo-HSCT, CAR19 T cells) indicated to vaccination against COVID19. 30 patients, 20 healthy volunteers vaccinated against COVID19.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 15
Exclusion Criteria
Uncompleted vaccination schedule.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method